factor β-activated kinase 1; TNBS: 2,4,6-trinitrobenzene sulfonic acid; TNF-R, TNF receptor; 34 WT: wild-type. 35 
36

Introduction 54
Crohn's Disease (CD) is an inflammatory bowel disease (IBD) that can affect any part 55 of the entire gastrointestinal tract. Genetic and epidemiological studies indicate that CD is a 56 complex, multifactorial disorder. Interplay between genetics and the environment promotes 57 development of gut abnormalities of autophagy, reticulum endoplasmic stress, innate and 58 adaptive immune responses, Th-1 and Th-17 polarization, intestinal barrier dysfunction and 59 microbial dysbiosis. [1] [2] [3] 
60
Nucleotide oligomerization domain 2 (NOD2, also known as NLR-C2 and CARD15) 61 is the most prominent susceptibility gene for CD. 4, 5 One-third to one-half of CD patients have 62 one or more NOD2 mutations. 6 Wild-type NOD2 is activated by muramyl dipeptides (MDP) 63 which are components of the bacterial cell wall, 7 but CD-associated NOD2 mutations prevent 64 MDP responses. 8 CD can therefore be considered as an immune deficiency with insufficient 65 responses to bacteria. Nevertheless, the exact mechanism by which NOD2 mutations 66 contribute to CD pathogenesis remains a matter of debate. [9] [10] [11] [12] 67 NOD2 regulates innate and adaptive immunity and intestinal permeability to maintain 68 intestinal homeostasis. [13] [14] [15] [16] Indeed, Nod2 ablation in mice leads to an increased bacterial 69 translocation across the small intestinal epithelium and excessive inflammatory cytokine 70 secretion. 14, 15 This reflects impaired crosstalk between inflammatory cytokine-secreting CD4 + 71
T-cells and epithelial cells that express myosin light chain kinase (MLCK). 15, 17 Similarly, 72 increased MLCK activity 18 and CD4 + T-numbers have been observed in the intestinal mucosa 73 of CD patients, 19, 20 and mouse models show that genetic activation of epithelial MLCK 74 induces increases in mucosal CD4 + T-numbers. 21 Anti-TNF-α antibody treatment restores the 75 intestinal barrier in CD patients. 22 Impaired epithelial barrier function may therefore be an 76 early event in CD lesions progression. 77
Here, we show that NOD2 expression in CD patients is not only increased in 78 inflammatory lesions but also at sites remote from injury. To define the mechanisms and 79 impact of this upregulation, we explored the remote consequences on the small intestinal 80 mucosa of a limited rectal injury induced by 2,4,6-trinitrobenzene sulfonic acid (TNBS). 81
82
Results
83
Epithelial NOD2 expression is increased in uninflamed mucosa of CD patients. 84
In CD patients, epithelial NOD2 expression is increased in mildly inflamed areas of 85 the digestive tract, remote from sites of injury. 23 To confirm NOD2 upregulation in remote 86 areas, we examined expression in ileal and/or cecal biopsies from 17 treatment-naïve pediatric 87 CD cases and five non-inflammatory controls. Although nine CD patients had heterozygous 88 mutations in NOD2 (1007fs n=3, R702W n=5 and R373C n=1), no histological differences 89
were seen between patients with wild type or mutant NOD2. Immunostains using two 90 different antibodies showed that NOD2 was weakly expressed by surface enterocytes and rare 91 mononuclear cells immediately below the epithelium in control ileum ( Figure 1A ). In contrast, 92 NOD2 expression was increased in ileum from CD patients ( Figure 1B We then determined NOD2 mRNA expression in the epithelial and lamina propria 98 compartments by qPCR after laser microdissection of biopsies from 8 patients. We observed 99 that NOD2 mRNA expression was inversely correlated in the epithelial and lamina propria 100 compartments of the same biopsy ( Figure 1G ). In the lamina propria, the average NOD2 copy 101 number was 43.1 in controls (normalized arbitrary units). In CD patients, similar values (43.6) 102 were observed in uninflamed areas whereas NOD2 expression was increased a 5-fold 103 (205.907) in the inflamed ileum. On the contrary, the mean values were 4.91 in epithelial cells 104 of controls and 4.6 in inflamed ileal areas but a 100-fold increase in NOD2 expression (660) 105 was detected in uninflamed ileum. Noteworthy, normal Paneth cells had low NOD2 106 expression in controls (1.43) . This expression was increased by inflammation and in 107 heterotopic colonic Paneth cells but NOD2 was mostly expressed by enterocytes. We thus 108 concluded that NOD2 expression is markedly increased in epithelial cells distant from 109 inflammatory lesions in CD patients. 110
111
Gut injury leads to epithelial Nod2 expression and cytokine production at remote 112 sites via CD4 + T-cell activation. 113
To confirm the expression of epithelial Nod2 in healthy areas distant from intestinal 114 lesions in a mouse model, we treated Nod2 wild-type (Nod2 WT ) mice by an intra-rectal 115 administration of TNBS. Instillation of TNBS in mice is known to induce a severe 116 inflammation in the distal colon.
14 Interestingly, TNBS has also been shown to alter the 117 biochemical activity of brush border enzymes (sucrase isomaltase and aminopeptidase), 118 mucins and cytokines levels in the small bowel (i.e. at a significant distance from the gut 119 injury) without histological lesions. 24 Three days after instillation, mice were sacrificed and 120 the severity of inflammation was assessed (Figure 2 ). In the distal colon, TNBS 121 administration induced a robust inflammation as evidenced by decreased body weight, 122 increased disease activity index (DAI), reduced colon length and high macroscopic Wallace 123 damage scores (Figure 2A-D) . Consistent with this phenotype, expression levels of TNF-α, 124
IFN-γ and IL-12 were increased ( Figure 2E ) at the site of colonic inflammation. 125
We next examined the small bowel but we did not find any overt inflammatory lesion 126 in the duodenum or ileum ( Figure 2F and G) despite increased TNF-α, IFN-γ and IL-12 127 proteins ( Figure 2H ) and mRNA ( Figure 2I ) levels. As observed in CD patients, expression of 128
Nod2 was increased in the duodenum, ileum and the uninflamed part of the colon remote from 129 rectal injury ( Figure 2I ). We hypothesized that this effect was consecutive to the recirculation 130 of CD4 + pro-inflammatory T-cells in the gut mucosa. We therefore treated TNBS-challenged 131 mice with anti-CD4 + monoclonal antibodies to reduce the number of CD4 + T-cells in the 132 small bowel ( Figure 2J ). This treatment only partially improved the colitis but restored 133 normal levels of Nod2 and inflammatory cytokines in the duodenum and ileum (Figure 2A-I) . 134 IFN-γ and TNF-α increase intestinal paracellular permeability via MLCK activation. 135
We therefore investigated whether the paracellular permeability of the small bowel was 136 affected in TNBS treated mice. [25] [26] [27] Paracellular permeability as well as long Mylk mRNA 137 expression were increased in both duodenum and ileum but returned to normal after CD4 + T-138 cell depletion ( Figures 2I and K 14 However, while TNBS-treated Nod2 WT mice exhibit no lesion in the small bowel 180 ( Figure 2F ), two thirds of Nod2 KO mice showed overt duodenal inflammatory lesions as 181
shown by a slight infiltration of scattered neutrophils in the lamina propria ( Figure 6E 7A-F). We thus concluded that mice carrying a CD associated mutation of NOD2 are not able 198 to contain the intestinal inflammation where the primitive inflammatory lesions occurred. 12 
199
Since Nod2 KO mice present a microbiota dysbiosis, we studied the contribution of gut 200 microbiota in the inflammatory phenotype using littermate mice cohoused for 6 weeks. To compare the role of hematopoietic vs non-hematopoietic NOD2 in the small bowel during 210 colitis, we compared Nod2 chimeric mice after bone marrow stem cell (BMSC) transfer from 211 WT BMSC (Figures 8D-H) . 222
Interestingly, ablation of Nod2 in the hematopoietic lineages led to a more frequent 223 and more severe inflammation in the ileum compared to chimeric mice expressing Nod2 in 224 the hematopoietic cells ( Figure 8I ). In parallel, expression levels of pro-inflammatory 225 cytokines levels and paracellular permeability were higher in mice deficient for Nod2 in 226 BMSC ( Figures 8J and K) . Consistent with the anti-inflammatory role of NOD2 in the 227 intestinal mucosa 36 , treatment with MDP improved the colonic inflammation but also the 228 severity of the small bowel inflammation and the expression in inflammatory cytokines in the 229 ileum only in chimeric mice expressing Nod2 in their hematopoietic compartment (Figures 230 8H-J). However, chimeric mice expressing NOD2 in their radio-resistant compartment 231
showed reduced paracellular permeability after MDP treatment regardless of the presence of 232 NOD2 in hematopoietic cells ( Figure 8K ). This provides additional evidence that both 233 hematopoietic and non-hematopoietic NOD2 exerts a protective function on the gut barrier. A "leaky gut" is a common feature of several conditions associated with NOD2 237 mutations including CD. Here we show that NOD2 protects the small intestine not only in 238 injured areas but also in areas remote from gut mucosal lesions. Indeed, NOD2 controls the 239 paracellular permeability all along the digestive tract to contain the inflammation to local 240 injuries and prevents its dissemination throughout the intestine. 241
We first observed that NOD2 expression was increased remote from primary 242 inflammatory lesions in naïve pediatric CD patients. Interestingly, the increase in NOD2 243 expression was not restricted to immune cells in inflammatory areas as it was also detected in 244 epithelial cells remote from CD lesions. We therefore hypothesized that epithelial NOD2 may 245 have a specific role in healthy intestinal areas and explored the intestinal barrier remote from 246 local injuries in mice. 247
The TNBS-induced colitis is a well-known model of self-limited inflammation. 248
Although TNBS is administered in the rectum, it also alters the small intestine without any 249 overt histological lesions in rats suggesting a remote effect of the colitis on the upper 250 intestine. 24, 37 In wild-type mice, we did not find any overt duodenitis or ileitis but we 251 observed an increase in pro-inflammatory cytokines (TNF-α and IFN-γ) concentration, 252 intestinal permeability and epithelial Nod2 expression in the small bowel. These effects were 253 reversed by anti-CD4 + antibodies or inhibitor of recirculated CD4 + T -cells suggesting that 254 they were consecutive to the recirculation of T-cells activated in the injured mucosa. 255
Pharmacologic or genetic MLCK inhibition limited permeability increases, indicating that 256 MLCK activation is a key component of the inflammatory response. Specifically, gut 257 permeability augmented TNF-α and IFN-γ expression and altered lamina propria immune 258 status. 21 Conversely, pro-inflammatory cytokines increased paracellular permeability by 259 stimulating MLCK expression and activity. 28, 29 260
Local colonic injury leads to the disruption of the small bowel barrier. Since Nod2 is 261 known to protect the gut barrier by inhibiting MLCK 15 and because it was over-expressed in 262 the small intestine, we supposed that it could restrain the leaky gut phenotype to the injured 263 mucosa. MDP-induced activation of Nod2 fully corrected the impairment of the small bowel 264
indicating that Nod2 plays a protective role along the small bowel. Recirculation of activated 265 T-cells increases the gut permeability but also induces NOD2 expression which, in turn, 266 strengthens the gut barrier. Interestingly, NOD2 seems to have little effect on the colitis itself. 267
The severity of the inflammation may thus limit the effect of Nod2. 268
In contrast to WT mice, Nod2-deficient or mutated mice developed overt 269 inflammatory lesions in the small bowel during TNBS-induced colitis, thus confirming the 270 relevance of NOD2 in the protection of the gut barrier. Using BMSC transfer experiments 271 (from Nod2
WT to Nod2 KO mice and vice-versa), we showed that both hematopoietic and non-272 hematopoietic NOD2 are necessary to protect the small bowel mucosa. 273
To the best of our knowledge, the role of NOD2 remote to colonic inflammation had 274 never been demonstrated. In CD, Th-1 oriented CD4 + T cells appear to be key effectors of gut 275 inflammation and NOD2 expression 38 and most treatments (anti-inflammatory drugs, 276
immune-suppressors and anti-TNF-α antibodies) target CD4 + T cells. For instance, TNF-α 277
antagonists diminish the severity of the disease and restore the gut barrier function. 22, 39 In our 278 model, Nod2 invalidation in the hematopoietic compartment is sufficient to promote a barrier 279 defect which is consistent with reported cases of CD patients cured by allogenic or autologous 280 hematopoietic stem cell transplantation. 40 However, activation of epithelial NOD2 may also 281 counteract the effect of IFN-γ and TNF-α suggesting that treatment of patients not carrying 282 mutations in NOD2 with NOD2 agonists could activate the negative feedback loop to prevent 283 the propagation of the inflammation and the skip lesions defining CD. 41 
284
Material and Methods 286
Patients and biopsies. 287
Intestinal biopsies were obtained from 17 untreated children during routine endoscopies 288 performed to establish CD diagnosis. Controls were histologically normal digestive biopsies 289 obtained from 5 children without inflammatory bowel disease. For each participant, one or 290 two biopsies from the ileum and/or cecum were sampled. Biopsies were either immediately 291 frozen and later stained with toluidine blue or fixed in 4%-phosphate-buffered formalin and 292 stained with hematoxylin and eosin. All biopsies were graded histologically so that 293 immunohistochemistry and laser microdissection could be correlated with disease severity. 294 NOD2 immunostaining was performed as previously described with two different rabbit 295 polyclonal antibodies (Cayman Chemical and a gift from G Thomas CEPH). 23 Laser 296 microdissection was performed on 7µm sections obtained from the frozen biopsies. After 297
verification of the quality of tissues and the absence of ulcers, surface epithelial cells and 298 lamina propria cells were laser-microdissected using a Leica R AS LMD system (Leica 299 microsystems) in less than one hour. A mean of 500 cells were microdissected from each of 300 the specimens (range 100-1000 cells) and stored in Trizol R reagent (Invitrogen, Groningen, 301
The Netherlands). The study was approved by the ethic committee "de protection des 302 personnes" (Saint Louis Hospital, Paris, France) and all the parents of participants provided a 303 signed informed consent. 304
Animal models. 305
Housing and experiments were conducted according to institutional animal healthcare 306 guidelines and were approved by the local ethical committee for animal experimentation 307 were generated or hosted in a pathogen free animal facility. 12, 14, 26 The 311 animal facility was monitored every six months in accordance with the full set of FELASA 312 high standard recommendations. The putative impact of Nod2-related dysbiosis on the studied 313 phenotypes was assessed using WT and Nod2 KO mice cohoused for 6 weeks in the same cage 314 where indicated. 33 30, 32 Chimerism was verified at 318 week 12 by flow cytometry using Ly5.1 and Ly5.2 congenic markers ( Figure 8A-C) . 35 
319
CD4
+ T-cells were depleted by two intra-peritoneal (i.p.) injections of 100μg purified 320 GK1.5 (anti-L3T4 (CD4 + ) monoclonal antibody (Pharmingen, Germany), 96 and 24 hours 321 before experimentation and 24hours after TNBS administration. 15 The effectiveness of CD4 + 322 depletion in Peyer's plates is shown in Figure 2J . To inhibit the recirculation of CD4 + T-cells, 323 mice were treated i.p. with FTY720 (3mg/kg; Sigma, France) 43 0, 1, 2 and 3 days after TNBS 324 infusion. 325 MLCK inhibition was achieved by ip injection of ML-7, 2 mg/kg body weight (Sigma, 326
France) twice daily during 4 days before experiments and 24 hours after TNBS 327 administration. 15 To investigate the effect of Nod2 stimulation, adult mice were pre-treated i.p 328 with muramyl dipeptide (MDP, 100µg/mice/day; Sigma, France) for 2 consecutive days 329 before experimentation and 24 hours after TNBS administration. A 100 µl aliquot of the freshly prepared solution was injected into the colon, 4 cm from the 336 anus, using a 3.5 F polyethylene catheter as previously described.
14 Body weight loss and 337 disease activity index were monitored before and 72h after TNBS administration. Mice were 338 sacrificed by cervical dislocation. Colonic length and macroscopic damage Wallace score 339 were recorded. 
ELISA. 369
Biopsies of duodenum, ileum and colon from different mice models were collected 370 and washed with cold PBS. These biopsies were then homogenized using an ultra-thurax in 1 371 ml of PBS1X and, the concentration of protein was determined using commercial kit (Biorad, 372
Marnes la Coquette, France). IFN-, IL-1β, IL-12 and TNF-α protein levels in the intestine 373 were determined by ELISA according to manufacturer's instructions (BD Biosciences). 46 
374
DNA extraction and real time quantitative PCR. 375
After extraction by the NucleoSpin RNA II Kit (Macherey-Nagel, France), total RNAs 376 were converted to cDNA using random hexonucleotides and then used for RT-PCR 377 (Invitrogen). We conducted qPCR with QuantiTect SYBR Green PCR Kit (Applied, France) 378 using sense and antisense primers specific for G3PDH, the long MLCK isoform -ΔΔCt as 383 previously described. 33 For RNA samples obtained by laser microdissection, NOD2 384 expression was measured in triplicate and normalized using the Abelson housekeeping gene. 385
To derive a relative number of mRNA molecules, a titration curve was established with 386 NOD2 plasmids (from 1 to 10 6 copy/microliters). 387
Statistical analysis. 388
For all the analysis, multigroup comparisons were performed using one-way ANOVA 389 statistics with Bonferroni correction for multiple comparisons where an unpaired t-test 390 assuming the Gaussian distribution was applied. The Gaussian distribution was tested by the 391 Kolmogorov-Smirnov test. Statistical analyzes were performed using GraphPad Prism 7.00 392 (GraphPad Software). A two-sided P-value < 0.05 was considered statistically significant. All 393 authors reviewed the data and approved the final manuscript. 394 395
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